41O Stock Chart & Stats
€0.52
€0.41(38.32%)
At close: 4:00 PM EDT
€0.52
€0.41(38.32%)
Day’s Range― - ―
52-Week Range€0.15 - €2.26
Previous CloseN/A
Volume600.00
Average Volume (3M)1.41K
Market Cap
€115.94M
Enterprise Value€224.61M
Total Cash (Recent Filing)€11.24M
Total Debt (Recent Filing)€18.43M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Dec 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding243,447,560
10 Day Avg. Volume1,127
30 Day Avg. Volume1,409
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.84
Price to Sales (P/S)19.10
P/FCF Ratio-0.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.49Price Target Upside1148.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)€39.23M
Bulls Say, Bears Say
Bulls Say
FDA-approved Product DifferentiationFDA approval gives Outlook a differentiated commercial product in a market currently served largely by repackaged bevacizumab. The approved label may support physician, payer, and practice adoption while creating a durable platform for U.S. commercialization.
Strong Clinical EfficacyThe registrational efficacy result provides meaningful clinical support for LYTENAVA's value proposition and marketing message. A differentiated outcome versus ranibizumab can strengthen physician confidence and improve the product's ability to compete over multiple quarters.
Defined Commercialization OpportunityManagement has articulated a sizable addressable market, revenue guidance, pricing, hiring plans, and reimbursement infrastructure for launch. This level of commercial preparation provides a clearer path from regulatory approval to recurring product revenue and potential operating scale.
Bears Say
Severely Stressed Balance SheetNegative equity and sharply higher TTM debt indicate a severely impaired capital structure with limited financial cushioning. This reduces flexibility to absorb commercialization setbacks, increases dependence on capital markets, and can constrain investment in the product launch.
Persistent Cash Burn And LossesYears of deeply negative operating and free cash flow show that the business has not yet converted its development platform into self-funding operations. Continued burn can require repeated external financing and may dilute shareholders before commercial revenues become meaningful.
Competitive Reimbursement BarriersLYTENAVA must overcome lower-cost alternatives and complex buy-and-bill reimbursement, while patient coinsurance can make the product materially more expensive than compounded options. These barriers could delay conversion, limit pricing power, and slow the planned revenue ramp.
Outlook Therapeutics News
41O FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was €0.15 and its highest was €2.26 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is €115.94M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2026 which is in 51 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2026. The company reported -€0.081 earnings per share for the quarter, missing the consensus estimate of -€0.072 by -€0.009.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 243,447,560 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -€0.081 in its last earnings report, missing expectations of -€0.072. Following the earnings report the stock price went down -5.915%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in DE:41O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.49 (1148.05% Upside)
€6.49 (1148.05% Upside)
Blogger Sentiment
Bullish
DE:41O Sentiment 83%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €2.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.52%
12-Months-Change
Fundamentals
Return on Equity
222.01%
Trailing 12-Months
Asset Growth
16.94%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
41O Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.View all DE:41O earnings summaries41O Stock 12 Month Forecast
Average Price Target
€6.49
▲(1148.05% Upside)